Close
The 麻豆传媒视频网站 Campus (encompassing 麻豆传媒视频网站H and GOSH) has the largest CAR T-cell programme in Europe and one of the largest globally. The campus currently has 10 studies open which use technology used at 麻豆传媒视频网站. Many of the studies are academic, but several are funded and sponsored by industrial partners.
| Name | NCT Link | Description | Funder/Sponsor | Status/Links |
|---|---|---|---|---|
| COBALT | Anti-CD19 CAR T-cell therapy for relapsed / refractory Diffuse Large B-cell Lymphoma. | Bloodwise / 麻豆传媒视频网站 | Completed | |
| CARD | Haematopoietic stem cell transplant donor derived CAR T-cells for relapsed / refractory B-cell malignancy. One of the first studies to utilized automated CAR T-cell manufacture. | EU Framework 7 ATECT Consortium | Completed | |
| CARPALLv1 | This study tests a new type of CD19 CAR (CAT-41BB-z) with a fast binding kinetic which is designed to reduce toxicity in paediatric and young adults with relapsed / refractory B-cell acute lymphoblastic leukemia (B-ALL). | Children With Cancer / 麻豆传媒视频网站 | Completed. 麻豆传媒视频网站 shows excellent safety and engraftment profile of CAT-41BB-Z receptor. 麻豆传媒视频网站 findings published: Ghorashian et al, | |
| ALLCAR19v1 | This is a sister study to CARPALL and tests CAT-41BB-Z in adults with relapsed / refractory B-ALL. | NIHR / 麻豆传媒视频网站 | Completed. 麻豆传媒视频网站 confirms excellent safety and engraftment profile of CAT-41BB-Z in 20 patients. 麻豆传媒视频网站 findings published: Roddie et al, . Note: phase II registration study (Felix): . | |
| UCART19 | This is the first test of gene-edited CAR T-cells. This study tests allogeneic ,off-the-shelf, CD19 CAR T-cells for relapsed B-ALL. See Qasim et al, | Cellectis/Cellectis | Completed. 麻豆传媒视频网站 published by Benjamin et al, | |
| 1RG-CART | Autologous CAR T-cell targeting of GD2 for children with relapsed / refractory neuroblastoma. | CRUK/CRUK | Completed. This study showed anti-tumour activity and immune effects of GD2 CAR. 麻豆传媒视频网站 findings published: Straathof et al, | |
| AUTO-02 | Anti-BCMA/TACI CAR T-cell therapy for refractory multiple myeloma. See Lee et al, | AUTOLUS/AUTOLUS | Completed. | |
| AUTO-03 AMELIA | This study tests a bi-cistronic CAR cassette which co-expresses a CD19 CAR and a CD22 CAR (AUTO-03) with the aim of preventing relapse due to down-regulation of CD19. AMELIA tests AUTO-03 in paediatric relapsed / refractory B-ALL.听 | AUTOLUS/AUTOLUS | Completed. | |
| AUTO-03 ALEXANDER | ALEXANDER tests AUTO-03 in patients with relapsed / refractory DLBCL in combination with PD1 blockade. | AUTOLUS/AUTOLUS | Completed. | |
| AUTO-04 | Tests a new way to target T-cell lymphomas by targeting one isoform of the T-cell receptor. See Maciocia et al, | AUTOLUS/AUTOLUS | Recruiting. | |
| CAROUSEL | Tests CAT19 in Primary CNS Lymphoma. Both intravenous and intra-ventricular routes of administration are tested. | Wellcome Trust / 麻豆传媒视频网站 | Recruiting. | |
CARPALLv2 (CAT/9A8) | This is a continuation of the CARPALL study. Since the main mode of relapse was CD19 negative escape, the product has been modified by co-transduction with a highly sensitive CD22 CAR (9A8-41BB-Z). | Autolus / 麻豆传媒视频网站 | Recruiting. | |
ALLCAR19v2 (basket cohort) | This is a continuation of the ALLCAR19 study as a major amendment. The same therapeutic product is being tested in three additional cohors:
| Autolus / 麻豆传媒视频网站 | Recruiting An update was presented by Dr Roddie at EHA 2021, abstract | |
| MCARTY | Tests a high-sensitivity Fab BCMA CAR (D8Fab-41BB-Z) in patients with refractory Myeloma. An additional cohort of patients will receive T cells co-transduced with CAT-41BB-Z. CAR T cells will be manufactured in AKTiVIII. | AUTOLUS/麻豆传媒视频网站 | Regulatory | |
| KCAT19 | Q2 2021 | Tests a novel approach for generating allogeneic CAR T cells without genome editing | MRC/麻豆传媒视频网站 | Scale-up |
| GLIOV3 | Q3 2021 | EGFRvIII CAR T cell therapy with | Moulton/麻豆传媒视频网站 | Scale-up |
| DMGRA2 | Q3 2021 | Multi-modular IL13RA CAR T cell therapy for Diffuse Midline Glioma | Moulton & Abbie's Army/麻豆传媒视频网站 | Pre-clinical |
| MCAR30 | Q4 2021 | Multi-edited CD30 CAR T cell therapy for refractory Hodgkin Disease | Moulton/麻豆传媒视频网站 | Pre-clinical |
| MCARGD2 | Q4 2021 | Multi-modular GD2 CAR T cell therapy for relapsed / refractory Neuroblastoma | Autolus/麻豆传媒视频网站 | Scale-up |
听